MARKET

MGTA

MGTA

Magenta Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.84
-0.35
-3.81%
Closed 16:00 05/29 EDT
OPEN
9.20
PREV CLOSE
9.19
HIGH
9.72
LOW
8.67
VOLUME
264.78K
TURNOVER
--
52 WEEK HIGH
16.87
52 WEEK LOW
5.76
MARKET CAP
349.04M
P/E (TTM)
-4.1573
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MGTA stock price target is 19.67 with a high estimate of 22.00 and a low estimate of 15.00.

EPS

MGTA News

More
Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a Phase I Trial Are Effective in Gene Therapy Settings
Business Wire · 05/14 13:00
Magenta Therapeutics To Present MGTA-145 Phase 1 Data At ASGCT
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of blood and immune reset to more patients, presented preclinical data on its stem cell
Benzinga · 05/14 12:28
Magenta Therapeutics (MGTA) Investor Presentation - Slideshow
Seeking Alpha - Article · 05/13 15:41
Avrobio Magenta Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 05/07 18:44
Magenta Therapeutics Q1 EPS $(0.510) Down From $(0.440) YoY
Magenta Therapeutics (NASDAQ:MGTA) reported quarterly losses of $(0.510) per share. This is a 15.91 percent decrease over losses of $(0.440) per share from the same period last year.
Benzinga · 05/07 11:51
Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business highlights and financial results for the first quarter ended Mar
Business Wire · 05/07 11:30
AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies
Business Wire · 05/06 12:00
Avrobio teams up with Magenta on novel conditioning agent for gene therapies
Seeking Alpha - Article · 05/06 11:31

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About MGTA

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company’s products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company’s C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.
More

Webull offers kinds of Magenta Therapeutics Inc stock information, including NASDAQ:MGTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGTA stock news, and many more online research tools to help you make informed decisions.